Inflammation and accelerated atherosclerosis: Basic mechanisms

被引:64
作者
Doria, A
Sherer, Y
Meroni, PL
Shoenfeld, Y [1 ]
机构
[1] Tel Aviv Univ, Chaim Sheba Med Ctr, Sackler Fac Med, Dept Med B,Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[2] Univ Padua, Dept Med & Surg Sci, Div Rheumatol, I-35128 Padua, Italy
[3] Univ Milan, IRCCS, Ist Auxol Italiano, Dept Internal Med,Allergy & Clin Immunol Unit, I-10249 Milan, Italy
关键词
D O I
10.1016/j.rdc.2005.01.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This article summarizes knowledge of the pathogenic mechanisms in autoimmune rheumatic diseases as risk factors for accelerated atherosclerosis. The studies described support a role for immunologic-inflammatory mechanisms in the pathogenesis of atherosclerosis. This immunologic-inflammatory state is evident in many autoimmune diseases, but also in the general population lacking an overt autoimmune disease. The ability to immunomodulate atherosclerosis (currently only experimental) should lead to future research into the mechanisms and treatment of atherosclerosis, the leading cause of death in the Western world.
引用
收藏
页码:355 / +
页数:9
相关论文
共 44 条
[31]   Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages [J].
Shapiro, S ;
Shoenfeld, Y ;
Gilburd, B ;
Sobel, E ;
Lahat, N .
CANCER, 2002, 95 (09) :2032-2037
[32]   Atherosclerosis [J].
Sherer, Y ;
Shoenfeld, Y .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (02) :97-99
[33]  
Sherer Yaniv, 2002, Autoimmunity Reviews, V1, P21, DOI 10.1016/S1568-9972(01)00003-9
[34]   Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? [J].
Shoenfeld, Y ;
Wu, RH ;
Dearing, LD ;
Matsuura, E .
CIRCULATION, 2004, 110 (17) :2552-2558
[35]  
Shoenfeld Y, 2000, SEM CLIN IMMUNOL, V1, P5
[36]  
Shoenfeld Yehuda, 2001, Trends in Immunology, V22, P293, DOI 10.1016/S1471-4906(01)01922-6
[37]   Antiinflammatory and immunomodulatory properties of statins [J].
Shovman, O ;
Levy, Y ;
Gilburd, B ;
Shoenfeld, Y .
IMMUNOLOGIC RESEARCH, 2002, 25 (03) :271-285
[38]   The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway [J].
Toubi, E ;
Shoenfeld, Y .
AUTOIMMUNITY, 2004, 37 (6-7) :457-464
[39]  
WU R, 1995, CLIN EXP IMMUNOL, V102, P174
[40]  
Wu R, 1999, CLIN EXP IMMUNOL, V115, P561